Background. Poststroke depression (PSD) is a common neuropsychiatric disorder that affects the disability, mortality, functional recovery, and quality of daily life of patients. Xiaoyao Recipe (XYR) is often used to treat PSD and has achieved good clinical effects, but it lacks reliable evidence. Objective. This study aims to evaluate the effectiveness and safety of XYR on PSD through meta-analysis. Methods. A comprehensive literature search was carried out in multiple databases, including PubMed, the Cochrane Library, Chinese Biomedical Literature Service System, China National Knowledge Infrastructure, Wanfang Database, VIP Database, and ClinicalTrials, from inception to July 1, 2021, to collect randomized controlled trials that applied XYR for patients with PSD. For a controlled trial, the search time limit was set from the time of the database’s establishment to July 2021. Two experienced researchers independently screened the literature according to the inclusion and exclusion criteria, extracted data, evaluated the quality of the literature, and used RevMan 5.3 software for meta-analysis. Results. A total of 12 studies were included in this study, involving 882 patients with PSD who were hospitalized or outpatients. The meta-analysis results showed that the total effective rate ( p < 0.00001 ) of the test group (XYR or XYR combined with antidepressants) after treatment was high; Hamilton’s Depression Scale score ( p < 0.000001 ), Scandinavian Stroke Scale score ( p = 0.004 < 0.05 ), and Barthel index ( p < 0.00001 ) were improved; the incidence of adverse reactions ( p < 0.00001 ) was low; and the serum serotonin content ( p < 0.00001 ) was high. Conclusion. Compared with antidepressant drugs, XYR is more effective and safer in the treatment of PSD patients. However, more high-quality studies are needed to further support the above conclusions.
Review question / Objective: One third of patients may have post-stroke depression after a stroke. Poststroke depression seriously affects rehabilitation outcome, quality of life and mortality of stroke patients. Data on preventive treatment of fluoxetine for post-stroke depression in this setting are inconsistent. The purpose of this systematic review was to explore the efficacy and acceptability of fluoxetine for early antidepressant therapy in stroke patients, so as to better provide evidence-based medical evidence for clinical practice. To this end, the systematic review to be considered will address the following issues: P: stroke patients; I: Treatment interventions included: fluoxetine (Prozac), control group: conventional treatment, plus placebo or no other intervention; O: Primary outcome: incidence of PSD, secondary outcome: Hamilton Scale, neurological dysfunction, daily living ability, mortality, incidence of adverse reactions; S: This review includes only randomized controlled studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.